JP2019208513A5 - - Google Patents

Download PDF

Info

Publication number
JP2019208513A5
JP2019208513A5 JP2019161819A JP2019161819A JP2019208513A5 JP 2019208513 A5 JP2019208513 A5 JP 2019208513A5 JP 2019161819 A JP2019161819 A JP 2019161819A JP 2019161819 A JP2019161819 A JP 2019161819A JP 2019208513 A5 JP2019208513 A5 JP 2019208513A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
bacterium
subject
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019161819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019208513A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019208513A publication Critical patent/JP2019208513A/ja
Publication of JP2019208513A5 publication Critical patent/JP2019208513A5/ja
Withdrawn legal-status Critical Current

Links

JP2019161819A 2010-06-18 2019-09-05 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス Withdrawn JP2019208513A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35616510P 2010-06-18 2010-06-18
US61/356,165 2010-06-18
US201161433598P 2011-01-18 2011-01-18
US61/433,598 2011-01-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017109331A Division JP6606124B2 (ja) 2010-06-18 2017-06-01 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス

Publications (2)

Publication Number Publication Date
JP2019208513A JP2019208513A (ja) 2019-12-12
JP2019208513A5 true JP2019208513A5 (enExample) 2020-07-27

Family

ID=44529869

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013515509A Expired - Fee Related JP6154320B2 (ja) 2010-06-18 2011-06-16 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス
JP2017109331A Expired - Fee Related JP6606124B2 (ja) 2010-06-18 2017-06-01 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス
JP2019161819A Withdrawn JP2019208513A (ja) 2010-06-18 2019-09-05 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013515509A Expired - Fee Related JP6154320B2 (ja) 2010-06-18 2011-06-16 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス
JP2017109331A Expired - Fee Related JP6606124B2 (ja) 2010-06-18 2017-06-01 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス

Country Status (5)

Country Link
US (2) US9340792B2 (enExample)
EP (1) EP2582800B1 (enExample)
JP (3) JP6154320B2 (enExample)
CN (2) CN103189504B (enExample)
WO (1) WO2011159880A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2793916A1 (en) * 2011-12-20 2014-10-29 North Carolina State University Methods to reduce polyposis and colorectal cancer
WO2013188529A1 (en) 2012-06-15 2013-12-19 Temple University Of The Commonwealth System Of Higher Education Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium
JP2015087167A (ja) * 2013-10-29 2015-05-07 キヤノン株式会社 画像処理方法、画像処理システム
WO2016124239A1 (en) * 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
GB201514302D0 (en) * 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Lactobacilli for treating cardiac dysfunction
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CN116655731A (zh) * 2023-06-30 2023-08-29 吉林大学 一条具有辅助治疗溃疡性结肠炎作用的蛋清肽序列及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6159447A (en) * 1997-10-16 2000-12-12 Pharmacal Biotechnologies, Llc Compositions for controlling bacterial colonization

Similar Documents

Publication Publication Date Title
Chua et al. Designer probiotics for the prevention and treatment of human diseases
Cano-Garrido et al. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes
Riaz Rajoka et al. Capacity of lactic acid bacteria in immunity enhancement and cancer prevention
WO2002016554A9 (en) Probiotics products containing lactic acid bacterium
CN1639317B (zh) 益生菌唾液乳杆菌菌株
KR101914248B1 (ko) 박테리아 균주를 함유한 조성물
CN103458709B (zh) 微囊化益生菌物质及其制造方法
Hanniffy et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health
WO2001097821A1 (en) Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
JP2019502737A5 (enExample)
JP5779762B2 (ja) 経口送達のための生細胞の配合物
HRP20160580T1 (hr) Upotreba bakterije streptococcus salivarius u liječenju kroničnih infekcija dišnog sustava
CN100402042C (zh) 增强肾功能的组合物及方法
US20150216932A1 (en) Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders
Yoon et al. A probiotic preparation duolac-gold ameliorates dextran sulphate sodium-induced mouse colitis by downregulating the expression of IL-6
Prakash et al. Toward a new generation of therapeutics: artificial cell targeted delivery of live cells for therapy
Pirolli et al. Therapeutic potential and translational challenges for bacterial extracellular vesicles in inflammatory bowel disease
O'Sullivan Genomics can advance the potential for probiotic cultures to improve liver and overall health
JP5088817B2 (ja) 乳酸菌とシソ科の植物とを含む組成物
TW202313076A (zh) 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷
Degré Cytokines and bacterial infections
JP2024545064A5 (enExample)
CN105770868B (zh) 重组乳酸菌及SNase在制备预防或治疗1型糖尿病药物中的应用
CN113186124B (zh) 一株能够缓解由脂多糖引起的急性肠道损伤的普通拟杆菌
CN116019225A (zh) 一种含有玉米肽的组合物及其应用